Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRPX4W)

Drug Name

ASP8497 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Type-2 diabetes	5A11	Preclinical	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Dipeptidyl peptidase 4 (DPP-4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Saxagliptin	DMGXENV	Type-2 diabetes	5A11	Approved	[3]
Sitagliptin	DMGDKXN	Cystic fibrosis	CA25	Approved	[4]
Alogliptin	DM8WI3R	Type-2 diabetes	5A11	Approved	[5]
Linagliptin	DMWFJTR	Non-insulin dependent diabetes	5A11	Approved	[6]
Vildagliptin	DMYN59P	Type-2 diabetes	5A11	Approved	[2]
Dapagliflozin Propanediol; Saxagliptin Hydrochloride	DM34TXO	Type-2 diabetes	5A11	Approved	[7]
Anagliptin	DMJXIC9	Type-2 diabetes	5A11	Approved	[8]
SaxaDapa FDC	DMAPRWV	Diabetic complication	5A2Y	Phase 3	[9]
LC-150444	DM09RKB	Type-2 diabetes	5A11	Phase 3	[10]
Dutogliptin	DMM5VTA	Type-2 diabetes	5A11	Phase 3	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity. Biochem Pharmacol. 2008 Jul 1;76(1):98-107.
2	Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
3	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
4	Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009 Oct;124(1):113-38.
5	Clinical pipeline report, company report or official report of Takeda (2009).
6	Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8	Diabetes Treatment. Diabetes Care. 2009 March; 32(3): e25-e30.
9	Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
10	Clinical pipeline report, company report or official report of ShangHai APIs Chemical.
11	Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55.